|
|
-
Aeterna Zentaris Posts Q1 EPS Of $0.07 Vs. Loss $0.65 Last Year
5/7/2013
|
-
Aeterna Zentaris Announces Transfer Of Manufacturing Rights Related To Cetrotide To Merck KGaA
4/17/2013
|
|
|
-
Aeterna Zentaris Appoints David Dodd As President & CEO
4/15/2013
|
|
|
|
|
|
|
|
|
-
Aeterna Zentaris Presents Encouraging Updated Proof-of-concept Results For Disorazol Z Cytotoxic Conjugates
4/10/2013
|